Veracyte, Inc. reported a significant increase in its financial performance for the third quarter of 2025, with total revenue reaching $131.9 million, a 14% increase from $115.9 million in the same period last year. The growth was primarily driven by a 17% rise in testing revenue, which amounted to $127.8 million, up from $109.5 million in the prior year. The company also reported a net income of $19.1 million, a 26% increase compared to $15.2 million in the third quarter of 2024. For the nine months ending September 30, 2025, total revenue was $376.5 million, reflecting a 15% increase from $327.1 million in the same period of 2024.
In terms of operational metrics, Veracyte reported a total test volume of 45,888 for the third quarter, an 18% increase from 39,032 tests in the same quarter of 2024. The company attributed the growth in testing revenue to a 19% increase in diagnostic tests reported, which was partially offset by lower prior period collections. However, biopharmaceutical and other revenue saw a decline of 74% year-over-year, primarily due to the deconsolidation of Veracyte SAS and a continued decline in biopharmaceutical services.
Strategically, Veracyte has been focusing on expanding its product offerings and integrating acquisitions. The company completed the acquisition of C2i Genomics, Inc. in February 2024, which is expected to enhance its capabilities in minimal residual disease detection. Additionally, Veracyte has ceased operations in its French subsidiary, Veracyte SAS, as part of a restructuring process, which has led to a loss on deconsolidation of approximately $6.7 million. The company is now working with Helio Diagnostics SAS for contract manufacturing of certain in vitro diagnostic products.
Looking ahead, Veracyte anticipates continued growth driven by its expanding portfolio of diagnostic tests, including the Percepta Nasal Swab test and the Prosigna breast cancer assay. The company is also focused on securing broader reimbursement from third-party payers and expanding its base of prescribing physicians. Despite the positive financial results, Veracyte remains cautious about potential macroeconomic challenges, including inflation and market volatility, which could impact its operations and financial performance in the future. The company ended the quarter with cash and cash equivalents of $315.6 million, up from $239.1 million at the end of 2024, indicating a strong liquidity position to support its growth initiatives.
About VERACYTE, INC.
Veracyte, Inc. is a global diagnostics company specializing in molecular tests for cancer and lung diseases. Its core offerings include genomic classifiers for thyroid, prostate, bladder, and lung cancers, delivered via CLIA labs and international in vitro diagnostic products. The company leverages AI, bioinformatics, and extensive clinical data to improve diagnosis, prognosis, and treatment decisions, aiming to enhance patient outcomes and reduce unnecessary procedures.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.